SimBioSys, a TechBio company focused on digital precision medicine for cancer care, announced its second FDA 510(k) clearance for TumorSight Viz. This updated platform is designed to aid breast surgeons in treatment planning and improve patient outcomes through enhanced AI-driven image processing and clinical decision support (CDS). The FDA clearance expands the use of TumorSight Viz by breast surgeons across the US.
Enhanced Capabilities of TumorSight Viz
The updated TumorSight Viz incorporates several key enhancements:
- Enhanced AI-Driven Segmentation: The platform utilizes AI to provide accurate and efficient tumor and tissue segmentation, enabling detailed 3D spatial visualization to support treatment planning.
- Clinical Decision Support (CDS) Application: The new CDS application is designed to provide data-driven insights for informing breast surgeons' planning and preparation for surgery.
- Direct MRI Access via PACS Systems: TumorSight Viz now supports integration with middleware software as well as direct to PACS systems, allowing automated access to MRI images for analysis within the TumorSight platform and seamless fit into the clinician workflow.
Clinical Impact and Alignment with Guidelines
The recent FDA mandate requiring breast density reporting for all women undergoing a mammogram is expected to increase the demand for MRI as a supplementary screening tool. TumorSight Viz offers healthcare providers a platform to visualize MRI data in 3D, supporting breast surgeons in tailoring treatment decisions to each patient's unique tumor characteristics. The platform's new CDS tool is designed to empower providers with advanced imaging insights and best practices for breast-conserving surgeries, aligning with updated NCCN guidelines promoting minimally invasive approaches when feasible and desired by patients.
According to Dr. Freya Schnabel from NYU, "TumorSight Viz's clinical decision support functionality provides a groundbreaking resource to assist breast surgeons and oncologists in considering the best possible approaches for each patient, fostering shared decision-making and precision care."
Addressing Breast Cancer Burden
Breast cancer affects more than 300,000 patients in the U.S. annually. SimBioSys's enhanced TumorSight platform combines advanced AI-driven visualizations with CDS tools, aiming to provide surgeons and patients greater confidence in their treatment decisions.
Company Statement
"This second FDA clearance represents a significant milestone in our mission to redefine precision medicine for cancer," said Barry Rosen, MD, Chief Medical Officer at SimBioSys. "TumorSight Viz's latest capabilities elevate the standard of breast cancer care by allowing surgeons to make more informed choices, moving closer to an era of precision surgery that reduces variation and supports breast conservation when desired by the patient."
